Post the presentation at the 2025 JPMorgan Healthcare Conference by SpringWorks Therapeutics (SWTX), JPMorgan says that while there are mixed views on Q4 Ogsiveo results, the firm continues to see a significant opportunity ahead of the product. JPMorgan also continues to see mirdametinib as an underappreciated asset overall. The firm continues to be a buyer of SpringWorks Therapeutics’ shares on today’s weakness on the long-term outlook of Ogsiveo/mirdametinib. JPMorgan has an Overweight rating on the name.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- TD sees ‘some disappointment’ with lack of SpringWorks Therapeutics M&A news
- SpringWorks Therapeutics Reports Strong 2024 Financial Results
- SpringWorks Therapeutics sees Q4 U.S. OGSIVEO net revenue $61.5M
- SpringWorks Therapeutics rumor highlighted in Betaville alert
- Biotech Alert: Searches spiking for these stocks today